Edwards Lifesciences Q3 2024 Adj. EPS $0.67 Beats $0.64 Estimate, Sales $1.354B Miss $1.522B Estimate
Portfolio Pulse from Benzinga Newsdesk
Edwards Lifesciences reported Q3 2024 earnings per share of $0.67, surpassing the analyst estimate of $0.64. However, their sales of $1.354 billion fell short of the expected $1.522 billion, marking an 8.58% decrease from the previous year.
October 24, 2024 | 8:23 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Edwards Lifesciences' Q3 2024 EPS of $0.67 beat expectations, but sales of $1.354B missed estimates and decreased 8.58% YoY.
The earnings per share exceeded expectations, which is positive, but the significant miss in sales and the year-over-year decline could offset the positive EPS impact, leading to a neutral short-term stock price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100